Name: Relias Media
Price range: $

Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)

Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.

RSV Vaccine for Older Patients Receives Support

FDA approved Arexvy to protect people age 60 years and older against the respiratory syncytial virus.

CDC: Be Wary of Travelers From African Outbreaks

Marburg virus has caused outbreaks in two African nations, and healthcare workers should be aware of travel history for incoming patients with classic hemorrhagic fever symptoms.

Healthcare Workers Not Likely Infected, Colonized with C. auris

Recent reports highlighting the continuing increase and geographic spread of Candida auris — a multidrug-resistant fungus that is moving between healthcare facilities — have raised the question of whether healthcare workers could be infected or colonized with the emerging pathogen. It is highly unlikely, but the risk is not zero.

First Oral Fecal Microbiota Product Wins FDA Approval

There is a new tool available in the battle against one of the most common healthcare-associated infections in the United States.

Researchers Use Advanced Technology to Detect MIS-C

Scientists want to improve diagnostic techniques for multisystem inflammatory syndrome in children, which became a confounding problem during the COVID-19 pandemic.

Viral Exposure and the Risk of Developing Neurodegenerative Disease

In two national European biobanks, researchers identified and replicated 22 pairs of viral exposures associated with a higher risk of neurodegenerative diseases.